UMARY ACID HYALURONIC — Class II drug recall D-0166-2025
Ongoing recall by MXBBB, reported 2025-01-01. cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be taint
| Recall number | D-0166-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | MXBBB, El Paso, TX, United States |
| Recall initiated | 2024-11-14 |
| Classified | 2024-12-26 |
| Reported by FDA | 2025-01-01 |
| Quantity | 321 bottles |
| Reason classes | undeclared allergen, cgmp |
| UPC / GTIN / UDI-DI | 07502265120323 |
| Lot numbers | 24183 |
| Expiration dates | 2028-07-01 |
Product
UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323
Reason for recall
cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0166-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.